Genetic characterization and epidemiological analysis of the first lumpy skin disease virus outbreak in Mongolia, 2021.

Novel lumpy skin disease virus (LSDV) strains of recombinant origin are on the rise in South East Asia following the first emergence in 2017, and published evidence demonstrates that such genetic lineages currently dominate the circulation. Mongolia reported first LSD outbreaks in 2021 in a north-eastern region sharing borders with Russia and China. For each of 59 reported LSDV outbreaks, the number of susceptible animals ranged from 8 to 8600 with a median of 572, while the number of infected animals ranged from one to 355 with a median of 14. Phylogenetic inferences revealed a close relationship of LSDV Mongolia/2021 with recombinant vaccine-like LSDV strains from Russia, China, Taiwan, Thailand and Vietnam. These findings support the published data that the circulating strain of LSDV belongs to the dominant recombinant lineage recently established in the region.

Assessing potential pathogenicity of novel highly pathogenic avian influenza (H5N6) viruses isolated from Mongolian wild duck feces using a mouse model.

Several novel highly pathogenic avian influenza (HPAIVs) A(H5N6) viruses were reported in Mongolia in 2020, some of which included host-specific markers associated with mammalian infection. However, their pathogenicity has not yet been investigated. Here, we isolated and evaluate two novel genotypes of A(H5N6) subtype in Mongolia during 2018-2019 (A/wildDuck/MN/H5N6/2018-19). Their evolution pattern and molecular characteristics were evaluated using gene sequencing and their pathogenicity was determined using a mouse model. We also compared their antigenicity with previous H5 Clade 2.3.4.4 human isolates by cross-hemagglutination inhibition (HI). Our data suggests that A/wildDuck/MN/H5N6/2018-19 belongs to clade 2.3.4.4h, and maintains several residues associated with mammal adaptation. In addition, our evaluations revealed that their isolates are less virulent in mice than the previously identified H5 human isolates. However, their antigenicity is distinct from other HPAIVs H5 clade 2.3.4.4, thus supporting their continued evaluation as potential infection risks and the preparation of novel candidate vaccines for their neutralization.